Roche Launches Test Assessing Drug Metabolism; First Target Is Psychiatrists
Roche Diagnostics is targeting psychiatrists via a medical education program as part of the launch of its AmpliChip CYP450 genomic test that assesses how patients metabolize certain drugs
You may also be interested in...
GlaxoSmithKline's Purinethol (mercaptopurine) should include labeling recommending use of pharmacogenetic testing to guide dosing, the Clinical Pharmacology Subcommittee of FDA's Pharmaceutical Science Advisory Committee concluded at its Oct. 23 meeting
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials